Table 1 Patient, tumour and treatment characteristics
Characteristic | Number (total = 172) | % | |
|---|---|---|---|
Age | Median (range) | 49 (27, 86) | |
Age group | <50 | 92 | 53.5 % |
> = 50 | 80 | 46.5 % | |
Laterality | Right | 92 | 53.5 % |
Left | 80 | 46.5 % | |
Breast location | Outter quadrant | 95 | 55.2 % |
Inner and/or central | 59 | 34.3 % | |
Unknown | 18 | 10.5 % | |
Clinical TNM stagea | |||
cT stage | 0-2 | 52 | 30.2 % |
3 | 91 | 52.9 % | |
4 | 29 | 16.9 % | |
cN stage | 0 | 69 | 40.1 % |
1 | 101 | 58.7 % | |
2 | 2 | 1.2 % | |
combined c stage | II | 111 | 64.5 % |
III | 61 | 35.5 % | |
Inflammatory | No | 153 | 89.0 % |
Yes | 19 | 11.0 % | |
Histology | Ductal carcinoma | 138 | 80.2 % |
Lobular carcinoma | 18 | 10.5 % | |
Other | 16 | 9.3 % | |
Grade | 1 | 8 | 4.7 % |
2 | 91 | 52.9 % | |
3 | 73 | 42.4 % | |
ER status | Negative | 64 | 37.2 % |
Positive | 101 | 58.7 % | |
Unknown | 7 | 4.1 % | |
HER2 status | Negative | 81 | 47.1 % |
Amplified | 33 | 19.2 % | |
Unknown | 58 | 33.7 % | |
NAC regimen | Anthracycline | 97 | 56.4 % |
Taxane | 16 | 9.3 % | |
Both | 54 | 31.4 % | |
Neither | 5 | 2.9 % | |
Surgery type | Lumpectomy | 90 | 52.3 % |
Mastectomy | 82 | 47.7 % | |
Axillary nodes | median (range) | 12 (1, 28) | |
<9 nodes | 39 | 16.7 % | |
Pathological TNM stagea | |||
yp T stage | 0-2 | 154 | 89.5 % |
3 | 13 | 7.6 % | |
4 | 2 | 1.2 % | |
unknown | 3 | 1.7 % | |
yp N stage | 0 | 95 | 55.2 % |
1 | 77 | 44.8 % | |
combined yp stage | pCR | 29 | 16.9 % |
I | 30 | 17.4 % | |
II | 104 | 60.5 % | |
III | 9 | 5.2 % | |
>1 node positive | No | 138 | 80.2 % |
Yes | 34 | 19.8 % | |
Trastuzumab use | No | 146 | 84.9 % |
Yes | 26 | 15.1 % | |
Radiotherapy schedule | 40/15 | 158 | 91.9 % |
(Gray/# fractions) | 50/25 | 11 | 6.4 % |
other | 3 | 1.7 % | |